Literature DB >> 12843341

Ethnic differences in markers of thrombophilia: implications for the investigation of ischemic stroke in multiethnic populations: the South London Ethnicity and Stroke Study.

Paula Jerrard-Dunne1, Andrew Evans, Rory McGovern, Cother Hajat, Lalit Kalra, Anthony G Rudd, Charles D Wolfe, Hugh S Markus.   

Abstract

BACKGROUND AND
PURPOSE: The role of hypercoagulable states in the pathogenesis of ischemic stroke in black subjects is not known, and data on normal reference ranges in black populations are lacking. This study estimated ethnic-specific reference ranges in a community population to determine the prevalence of thrombophilic states in a multiethnic stroke population.
METHODS: Free protein S, protein C, antithrombin III, activated protein C resistance, IgG anticardiolipin antibodies, and lupus anticoagulant were determined in 130 consecutive ischemic stroke cases < or =65 years of age (50 black Caribbeans, 30 black Africans, 50 whites) and 130 community controls.
RESULTS: Black African controls had significantly lower protein S (P<0.001) and protein C (P=0.049) and a trend toward lower antithrombin III (P=0.056) levels compared with white controls. Black Caribbean and African controls had higher diluted Russell's viper venom time ratios compared with whites (P=0.001, P<0.001). Using ethnic-specific reference ranges, 8 controls (6.3%) and 11 cases (8.5%) had thrombophilia abnormalities (odds ratio [OR], 1.39; 95% confidence interval [CI], 0.54 to 3.57; P=0.50). ORs were 0.96 (95% CI, 0.18 to 4.99; P=0.96) for whites, 1.57 (95% CI, 0.41 to 5.94; P=0.51) for black Caribbeans, and 2.07 (95% CI, 0.18 to 24.2; P=0.95) for black Africans.
CONCLUSIONS: Failure to account for ethnic differences in the normal reference ranges for thrombophilia markers may lead to inappropriate diagnosis and investigation of hypercoagulable states in black individuals. Protein S and protein C deficiencies and lupus anticoagulant may contribute to stroke risk in a minority of black cases, but they are unlikely to be major contributors to the excess stroke risk seen in young individuals of African and African-Caribbean descent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843341     DOI: 10.1161/01.STR.0000083049.65008.5F

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  6 in total

1.  Thrombophilias and stroke: diagnosis, treatment, and prognosis.

Authors:  Madeline C Fields; Steven R Levine
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

2.  Epidemiology of stroke in young adults: race/ethnic differences.

Authors:  Ji Y Chong; Ralph L Sacco
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

3.  Role of investigating thrombophilic disorders in young stroke.

Authors:  Kay W P Ng; Pei K Loh; Vijay K Sharma
Journal:  Stroke Res Treat       Date:  2011-02-08

4.  Country of residence is associated with distinct inflammatory biomarker signatures in HIV-infected patients.

Authors:  Maura Manion; Bruno B Andrade; Rebecca DerSimonian; Wenjuan Gu; Adam Rupert; Laura W Musselwhite; Juan G Sierra-Madero; Pablo F Belaunzaran-Zamudio; Ian Sanne; Michael M Lederman; Irini Sereti
Journal:  J Virus Erad       Date:  2017-01-01

5.  Coagulation Status and Venous Thromboembolism Risk in African Americans: A Potential Risk Factor in COVID-19.

Authors:  Galit H Frydman; Edward W Boyer; Rosalynn M Nazarian; Elizabeth M Van Cott; Gregory Piazza
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

6.  Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging.

Authors:  Yuanbing Jiang; Xiaopu Zhou; Fanny C Ip; Philip Chan; Yu Chen; Nicole C H Lai; Kit Cheung; Ronnie M N Lo; Estella P S Tong; Bonnie W Y Wong; Andrew L T Chan; Vincent C T Mok; Timothy C Y Kwok; Kin Y Mok; John Hardy; Henrik Zetterberg; Amy K Y Fu; Nancy Y Ip
Journal:  Alzheimers Dement       Date:  2021-05-25       Impact factor: 16.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.